Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for potential combination therapies using the immuno-oncology drug as the backbone.
Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
More from Anticancer
More from Therapy Areas
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.